Black Diamond Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net income of $37.5 million for the nine months ended September 30, 2025, a substantial improvement compared to a net loss of $53.7 million during the same period in 2024. This turnaround was primarily driven by a $70 million upfront payment received from Servier Pharmaceuticals under a licensing agreement for the development and commercialization of BDTX-4933, a targeted therapy for RAF/RAS-mutant solid tumors. The company did not report any license revenue in the previous fiscal period.
Operating expenses for the nine months ended September 30, 2025, totaled $39.9 million, down from $60.5 million in the prior year, reflecting a decrease in both research and development expenses and general and administrative costs. Research and development expenses were $27.3 million, a reduction from $39 million in 2024, attributed to operational efficiencies and a decrease in spending related to BDTX-4933 following its outlicensing. General and administrative expenses also fell to $12.6 million from $21.5 million, largely due to workforce efficiencies from a corporate restructuring.
In terms of operational metrics, Black Diamond Therapeutics reported a total of 56,943,413 shares outstanding as of September 30, 2025, an increase from 56,644,655 shares at the end of 2024. The company’s cash and cash equivalents stood at $30.9 million, down from $36.4 million at the end of the previous fiscal year, while total assets increased to $157.7 million from $122.6 million, driven by higher investments. The company’s accumulated deficit was reported at $449.6 million, reflecting its ongoing investment in research and development.
Looking ahead, Black Diamond Therapeutics anticipates continued operating losses as it advances its clinical programs, particularly for its lead product candidate, silevertinib, which is currently in Phase 2 trials for non-small cell lung cancer. The company expects its existing cash, cash equivalents, and investments to fund operations into the fourth quarter of 2027, but acknowledges the need for additional capital to support ongoing development and commercialization efforts. The company plans to pursue various funding avenues, including public and private equity offerings, collaborations, and licensing arrangements, to ensure it can meet its operational and strategic goals.
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies—oral, small molecule inhibitors targeting families of oncogenic mutations across genetically defined cancers. Its proprietary MAP drug discovery engine identifies and inhibits mutation-driven cancer proteins with selectivity and brain penetration. Key programs focus on EGFR-mutant non-small cell lung cancer and glioblastoma. The company aims to address resistance and expand targeted treatment options for patients with limited therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.